NRXP
Income statement / Annual
Last year (2024), NRx Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, NRx Pharmaceuticals, Inc.'s net income was -$25.13 M.
See NRx Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$5,000.00
|
$4,000.00
|
$2,000.00
|
$907,406.00
|
$0.00
|
$1.01 M
|
$0.00
|
| Gross Profit |
$0.00
|
-$5,000.00
|
-$4,000.00
|
-$2,000.00
|
-$907,406.00
|
$0.00
|
-$1.01 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$6.20 M
|
$13.37 M
|
$17.03 M
|
$20.26 M
|
$10.63 M
|
$3,495.65
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$13.51 M
|
$14.22 M
|
$27.37 M
|
$74.94 M
|
$11.44 M
|
$2,767.59
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
-$5,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.51 M
|
$14.21 M
|
$27.37 M
|
$74.94 M
|
$11.44 M
|
$2,767.59
|
$1.01 M
|
$0.00
|
| Other Expenses |
$0.00
|
$0.00
|
-$505,000.00
|
-$771,000.00
|
-$10.16 M
|
$713,187.00
|
$1.01 M
|
$0.00
|
| Operating Expenses |
$19.70 M
|
$27.58 M
|
$44.40 M
|
$94.43 M
|
$11.90 M
|
$6,426.10
|
$1.01 M
|
$0.00
|
| Cost And Expenses |
$0.00
|
$27.59 M
|
$44.40 M
|
$94.43 M
|
$11.90 M
|
$6,426.10
|
$1.01 M
|
$0.00
|
| Interest Income |
-$44,000.00
|
$494,000.00
|
$249,000.00
|
$18.00
|
$56.00
|
$1.21 M
|
$1.09 M
|
$0.00
|
| Interest Expense |
$230,000.00
|
$120,000.00
|
$0.00
|
$18,000.00
|
$56,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$5,000.00
|
$4,000.00
|
$2,000.00
|
$2,000.00
|
$0.86
|
$1.09 M
|
$52,516.00
|
| EBITDA |
-$18.50 M |
-$30.03 M |
-$39.75 M |
-$93.04 M |
-$51.72 M |
-$713,187.00 |
$82,412.00 |
-$105,036.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.62 M
|
-$2.57 M
|
$4.58 M
|
$22.73 M
|
-$39.88 M
|
$1.21 M
|
$1.09 M
|
-$105,033.00
|
| Income Before Tax |
-$25.13 M
|
-$30.16 M
|
-$39.82 M
|
-$93.06 M
|
-$51.78 M
|
$492,633.00
|
$82,412.00
|
-$105,033.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$9,000.00
|
-$4.58 M
|
-$21.35 M
|
-$39.43 M
|
$84,206.00
|
$16,311.00
|
$0.00
|
| Net Income |
-$25.13 M
|
-$30.15 M
|
-$35.24 M
|
-$71.72 M
|
-$12.35 M
|
$408,427.00
|
$66,101.00
|
-$105,033.00
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.39 |
-3.98 |
-0.54 |
-1.53 |
-0.36 |
0.8 |
0.0741 |
-0.12 |
| EPS Diluted |
-2.39 |
-3.98 |
-0.54 |
-1.53 |
-0.36 |
0.8 |
0.0741 |
-0.12 |
| Weighted Average Shares Out |
$10.52 M
|
$7.58 M
|
$65.77 M
|
$46.92 M
|
$34.27 M
|
$508,835.00
|
$892,496.00
|
$903,550.00
|
| Weighted Average Shares Out Diluted |
$10.52 M
|
$7.58 M
|
$65.77 M
|
$46.92 M
|
$34.27 M
|
$508,835.00
|
$892,496.00
|
$903,550.00
|
| Link |
|
|
|
|
|
|
|
|
